The production of human parvovirus capsid proteins in Escherichia coli and their potential as diagnostic antigens

References

1. Anderson M. J., Davis L. R., Hodgson J., Jones .S.E., Murtaza L., Pattison J. R., Stroud C. E., White J. M. 1982; Occurrence of infection with a parvovirus-like agent in children with sickle cell anaemia during a two year period. Journal of Clinical Pathology 35:744–749
   [Google Scholar]
2. Anderson M. J., Jones S. E., Fisher-Hoch S. P., Lewis E., Hall S. M., Bartlett C. L. R., Cohen B. J., Mortimer P. P., Periera M. S. 1983; Human parvovirus, the cause of erythema infectiosum (fifth disease)?. Lancet i:1378
   [Google Scholar]
3. Anderson L. J., Tsou C., Parker R. A., Chorba T. L., Wulff H., Tattershall P., Mortimer P. P. 1986; Detection of antibodies and antigens of human parvovirus B19 by enzyme-linked immunosorbent assay. Journal of Clinical Microbiology 24:522–526
   [Google Scholar]
4. Beard C., St Amand J., Astell C. R. 1989; Transient expression of B19 parvovirus gene products in COS-7 cells transfected with B19- SV40 hybrid vectors. Virology 172:659–664
   [Google Scholar]
5. Best J. M., Banatvala J. E. 1989; Rubella. In Principles and Practice of Clinical Virology pp. 315–353 Zuckerman A. J., Banatvala J. E., Pattison J. R. Edited by Chichester: John Wiley and Sons;
   [Google Scholar]
6. Brown T:, Ritchie L. D., Clewly J. P., Reid T. M. S. 1984; Intrauterine parvovirus infection associated with hydropsfetalis. Lancet ii:1033
   [Google Scholar]
7. Christie G. E., Farnham P. J., Platt T. R. 1981; Synthetic sites for transcription termination and a functional comparison with tryptophan operon termination sites in vitro . Proceedings of the National Academy of Sciences, U.S.A 78:4180–4184
   [Google Scholar]
8. Cohen B. J., Mortimer P. P., Pereira M. S. 1983; Diagnostic assays with monoclonal antibodies for the human serum parvoviruslike virus (SPLV). Journal of Hygiene 91:113–130
   [Google Scholar]
9. Cossart Y. E., Cant B., Field A. M., Widdows D. 1975; Parvovirus-like particles in human sera. Lancet i:72–73
   [Google Scholar]
10. Cotmore S. F., Mckie V. C., Anderson L. J., Astell C. R., Tattersall P. 1986; Identification of the major structural and non-structural proteins encoded by human parvovirus B19 and mapping of their genes by procaryotic expression of isolated genomic fragments. Journal of Virology 60:548–557
    [Google Scholar]
11. de Boer H. A., Comstock L. J., Vasser M. 1983; The tac promoter. A functional hybrid derived from the trp and lac promoters. Proceedings of the National Academy of Sciences, U.S.A 80:81–86
    [Google Scholar]
12. Duncan J. R., Cappellini M. D., Anderson M. J., Potter C. G., Kurtz J. B., Weatherall D. J. 1983; Aplastic crisis due to parvovirus infection in pyruvate kinase deficiency. Lancet ii:14–16
    [Google Scholar]
13. Hall S. M., Cohen B. J., Mortimer P. P., Caul E. O., Cradock-Watson J., Anderson M. J., Pattison J. R., Shirley J. A., Peto T. E. A. 1990; Prospective study of human parvovirus (B19) infection in pregnancy. Public Health Laboratory Service Working Party on Fifth Disease. British Medical Journal 1:1166–1170
    [Google Scholar]
14. Kakigaya S., Shimada T., Fujita S., Young N. 1989; A genetically engineered cell line that produces empty capsids of B19 (human) parvovirus. Proceedings of the National Academy of Sciences, U.S.A 86:7601–7605
    [Google Scholar]
15. Kelleher J. F., Lubon N. L. C., Mortimer P. P., Kamimura T. 1983; Human serum parvovirus: a specific cause of aplastic crisis in children with hereditary spherocytosis. Journal of Pediatrics 102:720–722
    [Google Scholar]
16. Kurtzman G. J., Cohen B. J., Field M. A., Oseas R., Blaese M., Young N. 1989; Immune response to B19 parvovirus and an antibody defect in persistent viral infection. Journal of Clinical Investigation 84:1114–1123
    [Google Scholar]
17. Laemmli U. K. 1970; Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature; London: 227680–685
    [Google Scholar]
18. Makoff A. J., Ballantine S. P., Smallwood A. E., Fairweather N. F. 1989; Expression of tetanus toxin fragment C in E. coli: its purification and potential use as a vaccine. Bio/Technology 7:1043–1046
    [Google Scholar]
19. Morinet F., D’Auriol L., Tratschin J. D., Galibert F. 1989; Expression of the human parvovirus B19 protein fused to Protein A in Escherichia coli: recognition by IgM and IgG antibodies in human sera. Journal of General Virology 70:3091–3097
    [Google Scholar]
20. Ozawa K., Young N. 1987; Characterization of capsid and noncapsid proteins of B19 parvovirus propagated in human erythroid bone marrow cell cultures. Journal of Virology 61:2627–2630
    [Google Scholar]
21. Ozawa K., Ayub J., Yu-Shu H., Hurtzman G., Shimada T., Young N. 1987; Novel translation map for the B19 (human) pathogenic parvovirus. Journal of Virology 61:2395–2406
    [Google Scholar]
22. Ozawa K., Ayub J., Young N. 1988; Translational regulation of B19 parvovirus capsid production by multiple upstream AUG triplets. Journal of Biological Chemistry 263:10922–10926
    [Google Scholar]
23. Pattison J. R., Jones S. E., Hodgson J., Davis L. R., White J. M., Stroud C. E., Murtaza L. 1981; Parvovirus infections and hypoplastic crisis in sickle cell anaemia. Lancet i:664–665
    [Google Scholar]
24. Porter H. J., Khong T. Y., Evans M. F., Chan V. T.-W., Fleming K. A. 1988; Parvovirus as a cause of hydropsfetalis: detection by in situ DNA hybridization. Journal of Clinical Pathology 41:381–383
    [Google Scholar]
25. Rao K. R., Patel A. R., Anderson M. J., Hodgson J., Jones S. E., Pattison J. R. 1983; Infection with parvovirus-like virus and aplastic crisis in chronic hemolytic anemia. Annals of Internal Medicine 98:930–932
    [Google Scholar]
26. Reid D. M., Brown T., Reid T. M. S., Rennie J. A. N., Eastmon C. J. 1985; Human parvovirus associated arthritis. A clinical and laboratory description. Lancet i:422
    [Google Scholar]
27. Schwartz T. F., Roggendorf M., Deinhardt F. 1988; Human parvovirus B19: ELISA and immunoblot assays. Journal of Virological Methods 20:155–168
    [Google Scholar]
28. Sergeant G. R., Mason K., Topley J. M., Sergeant B. E., Pattison J. R., Jones S. E., Mohamed R. 1981; Outbreak of aplastic crisis in sickle cell anaemia associated with parvovirus-like agent. Lancet ii:595–597
    [Google Scholar]
29. Shade R. O., Blundell M. C., Cotmore S. F., Tattersall P., Astell C. R. 1986; Nucleotide sequence and genome organization of human parvovirus B19 isolated from the serum of a child during aplastic crisis. Journal of Virology 58:921–936
    [Google Scholar]
30. Sisk W. P., Berman M. L. 1987; Expression of human parvovirus B19 structural protein in E. coli and detection of antiviral antibodies in human serum. Bio/Technology 5:1077–1080
    [Google Scholar]
31. Towbin H., Staehelin T., Gordon J. 1979; Electrophoretic transfer of proteins from polyacrylamide gels to nitrocellulose sheets: procedure and some applications. Proceedings of the National Academy of Sciences, U.S.A 76:4350
    [Google Scholar]
32. Twigg A. J., Sherratt D. J. 1980; Trans-complementable copy-number mutants plasmid ColE1. Nature; London: 283216–218
    [Google Scholar]
33. West N. C., Meigh R. E., Mackie M., Anderson M. J. 1986; Parvovirus infection associated with aplastic crises in a patient with HEMPAS. Journal of Clinical Pathology 39:1019–1020
    [Google Scholar]
34. Winther M. D., Allen G., Bomford R. H., Brown F. 1986; Bacterially expressed antigenic peptide from foot-and-mouth disease virus capsid elicits variable immunologic responses in animals. Journal of Immunology 136:1835–1840
    [Google Scholar]